Search

Displaying results 9471 - 9480 of 10000 in total
  1. Drug

    Fosgemcitabine palabenamide

    go.drugbank.com/drugs/DB15057
    Investigational

    NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).

    Categories: Heterocyclic Compounds, 1-RingSynonyms: Fosgemcitabine palabenamide, p(rs)-, N-[[P(S)]-2'-deoxy-2',2'-difluoro-P-phenyl-5'-cytidylyl]-L-alanine phenylmethyl ester
  2. Drug

    Utomilumab

    go.drugbank.com/drugs/DB15113
    Investigational

    Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).

  3. Drug

    Fibronectin

    go.drugbank.com/drugs/DB15150
    Investigational

    Fibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).

  4. Drug

    Etentamig

    go.drugbank.com/drugs/DB17268
    Investigational

    TNB-383B is a CD3 and B-cell maturation antigen T-cell engaging bispecific antibody.

    Synonyms: Anti-BCMA x aCD3 T-BsAb TNB-383B, Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383
  5. Drug

    NC-6300

    go.drugbank.com/drugs/DB17341
    Experimental

    NC-6300, also known as K-912, is a novel [epirubicin] drug-conjugated polymeric micelle.

  6. Drug

    P-BCMA-101

    go.drugbank.com/drugs/DB17371
    Investigational

    P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.

    Synonyms: Autologous T-cells transfected with PiggyBac transposon plasmid vector expressing B-cell maturation antigen (CAR-T cells)
  7. Drug

    gp209-2M antigen

    go.drugbank.com/drugs/DB17462
    Investigational

    The gp209-2M antigen is derived from gp209, and has potential immunomodulatory and antineoplastic activities.

  8. Drug

    AAV-RPE65

    go.drugbank.com/drugs/DB18343
    Experimental

    AAV-RPE65 is an adenovirus associated viral vector serotype 5 containing the human RPE65 gene

  9. Drug

    WU-NK-101

    go.drugbank.com/drugs/DB18350
    Investigational

    WU-NK-101 is an allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product

  10. Drug

    ASP-2138

    go.drugbank.com/drugs/DB18473
    Investigational

    ASP-2138 is a bispecific antibody directed against CLDN18.2 and T cell receptor complex CD3